Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disease. The accumulation of α-synuclein protein in the basal ganglia is the underlying pathogenesis of PD. Genetic abnormalities are one of the predisposing factors for PD. PDs with GBA gene mutations have abnormalities coding for β-glucocerebrosidase (GCase) enzymes in lysosomes, which lead to increased accumulation of α-synuclein. Ambroxol has long been known as a therapy for airway disorders which also has antioxidant benefits. However, recently, there have been many experimental studies examining the benefits of ambroxol in neurodegenerative diseases, including PD. This study aims to examine experimental studies of ambroxol administration in PD.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
